BIT's 16th Annual World Congress of
Drug Discovery Science & Technology - Jinan 2018
Theme: Focusing on Biomedical Frontiers, Driving Industrial Innovative Development
Time: November 6-8, 2018
Place: Jinan, China
Preliminary Scientific Program
Session times on those days will not be finalized until the overall program schedule is completed.
Program Sessions (Please click each Forum for detailed program information) |
Stream 4101: New Anti-cancer Drug R & D | |
Time: 13:30-17:30, Nov. 6, 2018 |
|
Chair |
Dr. Rashida A. Karmali, CEO & President, Tactical Therapeutics, Inc., USA |
Co-Chair |
Dr. Chin-Tarng Lin, Professor Emeritus of Pathology, National Taiwan University Hospital, Taiwan |
13:30-13:35 |
Chair's Introduction |
13:35-13:55 |
Title: Rational Combination of in Vivo Cancer Antigen Priming and Adoptive T-cell Therapy Mobilizes Immune and Clinical Responses in Cancer Patients |
13:55-14:15 |
Title: Discovery of a New Generation of Tubulin Inhibitors Overcoming Taxane Resistance for Cancer Therapy |
14:15-14:35 |
Title: Phase IB Trial of Carboxyamidotriazole Orotate in Glioblastoma and Anaplastic Gliomas |
14:35-14:55 |
Title: Development of the Preclinical Efficacy Evaluation Platform for Novel Anti-cancer Drugs |
14:55-15:15 |
Title: Physicochemical Characterization of the Oolong Tea Polysaccharides with High Molecular Weight and their Synergistic Effects in Combination with Polyphenols on Hepatocellular Carcinoma |
15:15-15:30 |
Coffee Break |
15:30-15:50 |
Title: The Efficacy of Targeting Peptides for MRI Analysis and Chemotherapy for Nasopharyngeal Carcinoma and Breast Cancer |
15:50-16:10 |
Title: Role of Natural Antioxidants in Cancer Chemotherapy |
16:10-16:30 |
Title: Discovering Anti-metastasis New Drugs |
16:30-16:50 |
Title: Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics |
16:50-17:10 |
Title: Study of the Molecular Mechanism of Vitamin K2 Activates AMPK, Suppressing the Growth of, as well as Inducing the Death of, Bladder Carcinoma Cells via PDK1-dependent Metabolic Reprogamming |
17:10-17:30 |
Title: Biochemical Studies on the Effect of Quercetin along with Adriamycin on DEN induced Experimental Hepatocellular Carcinoma |
Stream 4102: The Treatment and Nursing for Geriatric Disease |
|
Time: 15:30-17:15, Nov. 6, 2018 |
|
Chair |
Dr. Miroslava Navratilova Ph.D., Internal Medicine and Nutrition Specialist, University Hospital Brno and Medical Faculty of Masaryk University, Czech Republic |
Co-Chair |
Mr. Radim Mottl, Senior Designer, MidsundBruk AS, Czech Republic |
15:30-15:35 |
Chair's Introduction |
15:35-16:00 |
Title: Influence of Nutritional Support on Nutritional and Mental Status in Dementia Patients with Alzheimer's Disease, Influence on Cognitive Functions. Metabolic specificity of eating disorders. Comparative and Intervention Study |
16:00-16:25 |
Title: The Pattern of Antimicrobial Use for Geriatric Palliative Inpatients During the Last Week of Life |
16:25-16:50 |
Title: Treatment of Nocturia with Novel Immediate/Sustained Release of Acetaminophen and Ibuprofen(Paxerol®): Results from a Multi-Center, Randomized, Double Blinded, Placebo-Controlled Study |
16:50-17:15 |
Title: Supportive Cancer Care for Older Adults |
Stream 4103: Drug R & D and Therapies for Diabetes and Other Metabolic Diseases |
|
Time: 10:30-12:15, Nov. 7, 2018 |
|
Chair |
Dr. I. G. Danilova, Professor, Ural Federal University, Russia |
Co-Chair |
Dr. Tianhua Niu, Research Assistant Professor, Tulane University School of Medicine, USA |
10:30-10:35 |
Chair's Introduction |
10:35-10:55 |
Title: Pharmacogenetics of Response to Sulfonylurea Treatment of Type 2 Diabetes Mellitus: Embracing a Path towards Precision Medicine |
10:55-11:15 |
Title: Partial Rrecovery of Pancreatic Insulin-producing System from Diabetes Mellitus by Sodium Phthalhydrazide in Rats |
11:15-11:35 |
Title: Translational Model of NASH in Obese and Diabetic Nonhuman Primates |
11:35-11:55 |
Title: New Drugs for type 2 diabetes: Current Status and Future Prospects |
11:55-12:15 |
Title: Healing of Diabetes Type1, Type2 and Type3/LADA without Any Medicines |
Stream 4104: New Drug R & D for Major Diseases |
|
Time: 15:30-17:15, Nov. 7, 2018 |
|
Chair |
Dr. Jian Guan, Associate Professor, The University of Auckland, New Zealand |
Co-Chair |
Dr. Mei-Hua Qu, Professor, Weifang Medical University, China |
15:30-15:35 |
Chair's Introduction |
15:35-15:55 |
Title: Neuroreceptors and Neurotransmitters: Latest Frontiers for Psychotropic Drug Development |
15:55-16:15 |
Title: The Role for IGF-1 Derived Small Neuropeptide as a Therapeutic Agent and Biomarker for Neurological Disorders |
16:15-16:35 |
Title: Chemopreventive Effect of Myricetin, A Natural Occurring Compound, on Colonic Chronic Inflammation and Inflammation-driven Tumorigenesis in Mice |
16:35-16:55 |
Title: Bio Electron's Laser Acupuncture by KBTE Medical laser Device |
16:55-17:15 |
Title: PEGylation of Curcumin Can Effectively Improve the Bioavailability and Pharmacological Activity of Curcumin Parent |
17:15-17:35 | Title: Humanin Derivatives Inhibit Necrotic Cell Death in Neurons Dr. Abraham H. Parola, Emeritus Professor, Ben Gurion Unibersity of the Negev, Israel |
Stream 4201: Gene Therapeutics & RNAi Drug Discovery |
|
Time: 08:30-10:15, Nov. 7, 2018 |
|
Chair |
Dr. Jeffrey Hung, Chief Commercial Officer, GM of cGMP Business, Vigene Biosciences, Inc., USA |
08:30-08:35 |
Chair's Introduction |
08:35-09:00 |
Title: Next Generation RNA Therapeutics: Locked Nucleic Acid |
09:00-09:25 |
Title: Gene Therapy- A Frontier of Biopharmaceutical Development- Promises, Bottlenecks and Technologies |
09:25-09:50 |
Title: Remote Drug Delivery via Modulating the Refraction in the Wave Optics of Chromosomes |
09:50-10:15 |
Title: Carboxy therapy in the Management of Malum Perforans Pedis in a Diabetic Patient |
Stream 4202: Next Generation Biotherapy (Topics: Antibody Therapy; Cell Therapy; Cancer Immunotherapy) |
|
Time: 10:30-12:35, Nov. 7, 2018 |
|
Chair |
Dr. Qiao Li, Associate Professor, University of Ottawa, Canada |
10:30-10:35 |
Chair's Introduction |
10:35-10:55 |
Title: Strategies for Preclinical evaluation of Antibody drug Conjugates |
10:55-11:15 |
Title: De-immunogenicity of Antibody Drug by Removing B Cell Epitope |
11:15-11:35 |
Title: Chromatin States Associated with Transcription Regulators in Stem Cell Differentiation |
11:35-11:55 |
Title: SOTIO Autologous Cell Therapy GMP Manufacturing. |
11:55-12:15 |
Title: Conduct of Pediatric Clinical Trials: Challenges and Opportunities |
12:15-12:35 |
Title: Treatment of Autoimmune Diseases with Anti-IL-39 Antibody |
Ji'nan Branch of China Council for The Promotion of International Trade
University of South Australia
School of Biological Engineering, Qilu University of Technology
![]() Jinan Innovation Zone Life Science Development City |
![]() |
BIT Group Global Ltd. |
Amgen, Inc.
Arrowhead Pharmaceuticals Inc.
Eisai Co., Ltd.
ChemDiv, Inc.
University of Queensland
Comenius University
Fountain Medical Development Ltd.,
McGill University
Pharmaron Inc.
Pfizer Inc.
Florida State University
Shanghai Jiaotong University School of Medicine
Leydig, Voit & Mayer, Ltd.
University of Pittsburgh
F. Hoffmann-La Roche
Tactical Therapeutics, Inc.
Leadscope Inc.
AbbVie Deutschland GmbH & Co. KG
Merck KGaA
Genentech, Inc.
Sanofi
Hamamatsu Photonics K.K.
University of Arizona
ChemDiv, Inc
AbMax Biotechnology Inc.
University Hospital Brno and Medical Faculty of Masaryk University
PSMMC, Riyadh
Boehringer Ingelheim Pharma GmbH & Co. KG
Global PKPD & Pharmacometrics, Eli Lilly and Company
Beijing Institute of Pharmacology and Toxicology
Auckland UniVersity
Cyclenium Pharma Inc.
Helmholtz Centre for Infection Research
University of Arizona
Medlab Clinical Pty Ltd.
National Institute of Biological Sciences, Beijing
Quinnipiac University/King Lee PhD, LCC
Novartis Institue of Biomedical Research
IriSys, LLC,
Private Clinic of Dermatovenerology Svidník
Saarland University
Cardiff University
Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609-826, Fax: 0086-411-84796897
Copyright © 2017-2018 BIT Congress Inc.